SAM
ENGN icon

Sectoral Asset Management’s enGene Therapeutics ENGN Stock Holding History

Sectoral Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.5K Buy
+21,700
New +$88.5K 0.03% 82
2025
Q2 		– Sell
-11,700
Closed -$52.4K – 101
2025
Q1 		$52.4K Sell
11,700
-67,219
-85% -$417K 0.04% 84
2024
Q4 		$525K Sell
78,919
-15,300
-16% -$119K 0.35% 56
2024
Q3 		$622K Buy
+94,219
New +$701K 0.37% 61

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Sectoral Asset Management's ENGN Position: Q2 2026 in Review

Sectoral Asset Management opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 21,700 shares worth $37.5K. The stake represents 0.03% of the portfolio and ranks #82 among its holdings. This is a return to the name: Sectoral Asset Management previously reported a position in ENGN as recently as Q1 2025.

Sectoral Asset Management first reported a position in ENGN in Q3 2024 and has held it in 4 quarters since. The position peaked at $622K in Q3 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Sectoral Asset Management held 21,700 shares of enGene Therapeutics worth $37.5K as of Q2 2026.
  • enGene Therapeutics was a new Sectoral Asset Management position in Q2 2026.
  • enGene Therapeutics made up 0.03% of Sectoral Asset Management's portfolio in Q2 2026, its #82 holding.
  • Sectoral Asset Management first reported a position in enGene Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Sectoral Asset Management's enGene Therapeutics position peaked at $622K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.